Sorting Nexin 10 sustains Platelet-Derived Growth Factor Receptor signaling in glioblastoma stem cells via endosomal protein sorting

Ryan C. Gimple^{1,2,*}, Guoxin Zhang^{1,*}, Shuai Wang³, Tengfei Huang³, Jina Lee³, Suchet Taori³, Deguan Lv^{1,3}, Deobrat Dixit^{1,4}, Matthew E. Halbert^{5,6}, Andrew R. Morton², Reilly L. Kidwell¹, Zhen Dong⁷, Briana C. Prager^{1,2}, Leo Kim^{1,2}, Zhixin Qiu^{1,3}, Linjie Zhao^{1,3}, Qi Xie^{1,8,9,10}, Qiulian Wu^{1,3}, Sameer Agnihotri^{3,5,6}, Jeremy N. Rich^{1,3,11-13,†}

¹Division of Regenerative Medicine, Department of Medicine, University of California, La Jolla, CA 92037, USA

²Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA

³UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA

⁴Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

⁵Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

⁶John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

⁷La Jolla Institute for Immunology, La Jolla, CA 92037

⁸Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.

⁹Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.

¹⁰Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China

¹¹Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037

¹²Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

¹³Department of Neurosciences, University of California, La Jolla, CA 92037

*, These authors contributed equally.

Correspondence: Jeremy N. Rich (drjeremyrich@gmail.com)

5150 Centre Avenue, 5th Floor, Pittsburgh, PA 15232. 412-623-3364.

Key words: glioblastoma, glioblastoma stem cell, cancer stem cell, endosome, SNX10, PDGFR Conflict of Interest Statement: The authors have declared that no conflicts of interest exist.



SUPPLEMENTARY FIGURE LEGENDS

Figure S1: Gene set enrichment analysis of targets identified through combinatorial epigenetic and transcriptional profiling

- A. Gene set enrichment analysis (GSEA) plots of selected pathways upregulated in GSCs vs. NSCs by RNA-sequencing. FDR q-value was calculated for statistical analysis.
- B. Gene set enrichment analysis (GSEA) plots of selected pathways upregulated in GSCs vs. NSCs by ChIP-sequencing. FDR q-value was calculated for statistical analysis.
- **C.** HOMER de novo motif analysis of GSC-specific H3K27ac peaks.
- D. Gene set enrichment analysis (GSEA) of 180 overlapping candidate genes identified in Figure 1G.
- E. Gene set enrichment connectivity diagram showing top gene set enrichments and individual component genes of 180 overlapping candidate genes identified in Figure 1G.





Figure S2: Targeted CRISPR screen quality control metrics.

- **A.** q-RTPCR analysis of mRNA expression of GFAP and OLIG2 in paired GSCs and DGCs. **, p<0.01; ***, p<0.001.
- **B.** Total number of reads from each CRISPR screening sample with percentage of mapped and unmapped reads.
- **C.** Log10 of sgRNA counts from each CRISPR screening sample.
- **D.** Gini index from each CRISPR screening sample.
- E. Combined analysis of CRISPR screening data in all six GSCs. Negative beta-value indicates essentiality and log2 transformed wald p-value indicates significance.



Figure S3: Validation of targeted CRISPR screening targets and SNX10 expression

- **A.** Western blot showing transduction of the FLAG-tagged CRISPR-Cas9 construct in GSC3565 for individual sgRNA validation experiments.
- B. Normalized cell viability of GSC 3565 following transduction with sgRNAs targeting OLIG2, NOS2, AKR1B10 or HOXA7 or a non-targeting sgRNA (sgCONT) over a 7-day time course. Repeated measures two-way ANOVA with Dunnett multiple test correction was used for statistical analysis.
- C. Overlay of H3K27ac signal at the SNX10 locus across an overlay of 38 GSC and 5 NSCs.



Figure S4: SNX10 knockdown reduced cell proliferation in GSCs and contributed to apoptotic cell death.

- A. Normalized cell viability of GSC MGG8, GSC CW738, GSC CW839, and GSC 2012 following transduction with one of three shRNAs targeting SNX10 compared to a nontargeting shRNA (shCONT) over a 6 day time course. N=3. Data are presented as mean ± SD. Significance was determined by two-way ANOVA with Tukey's multiple comparisons. *, p < 0.05; **, p < 0.01; ***, p<0.001.</p>
- B. Western blot showing SNX10 protein levels in MES28, CW468 and 3565 following knockdown of SNX10 with two independent shRNAs. Tubulin was used as a loading control.
- C. Western blot showing SNX10 protein levels in NSC11, ENSA, and hNP1 following knockdown of SNX10 with two independent shRNAs. Tubulin was used as a loading control.
- D. Western blot showing SNX10 protein levels in DGC MES28, DGC CW468, and DGC 3565 following knockdown of SNX10 with two independent shRNAs. Tubulin was used as a loading control.
- E. Flow cytometry of Annexin V/ Propidium iodide (PI) stained GSC 3565 transduced with shCONT or one of three shRNAs targeting SNX10.
- **F.** Flow cytometry of Annexin V/ Propidium iodide (PI) stained GSC MES28 transduced with shCONT or one of three shRNAs targeting SNX10.



CW468

Figure S5: SNX10 is important for maintenance of GSC stemness pathways and for endosomal PDGFRβ signaling

- A. mRNA expression of SOX2 (left) and OLIG2 (right) in GSC 3565 measured by qPCR following transduction with three independent non-overlapping shRNAs targeting SNX10 or a non-targeting control shRNA (shCONT). N=3. Data are presented as mean ± SD. Significance was determined by oneway ANOVA with Tukey's multiple comparisons. ** p<0.01, *** p<0.001.</p>
- B. mRNA expression of SOX2 (left) and OLIG2 (right) in GSC MES28 measured by qPCR following transduction with three independent non-overlapping shRNAs targeting SNX10 or a non-targeting control shRNA (shCONT). N=3. Data are presented as mean ± SD. Significance was determined by one-way ANOVA with Tukey's multiple comparisons. ** p<0.01, *** p<0.001.</p>
- C. Western blot of PDGFRβ and SOX2 in GSC 3565 or GSC CW468 following transduction with different sgRNAs targeting SNX10 compared to a nontargeting sgRNA (sgCONT). TUBULIN was used as loading control.
- D. Western blot showing protein levels of selected receptor tyrosine kinases and downstream signaling factors in GSC CW468 following transduction with one of two sgRNAs targeting SNX10 or a non-targeting sgRNA (sgCONT). Tubulin was used as a loading control. Samples were run contemporaneously on separate gels with individual loading controls shown in Supplementary information.
- E. Western blot showing protein levels of selected receptor tyrosine kinases and downstream signaling factors in GSC CW468 following transduction with one of three shRNAs targeting SNX10 or a non-targeting shRNA (shCONT). Tubulin was used as a loading control. Samples were run contemporaneously on separate gels with individual loading controls shown in Supplementary information.



Figure S6: SNX10 portends poor prognosis in proneural subtype of glioblastoma patients.

- A. Immunofluorescence images of EdU positive cells in different GSCs transduced with shCONT or one of two shRNAs targeting PDGFRβ. EdU is in red, DAPI in blue. Scale bars represent 20µm.
- B. Quantification of EdU positive cells in different GSCs transduced with shCONT or one of two shRNAs targeting PDGFRβ. N = 3. Data are presented as mean ± SD. Significance was determined by one-way ANOVA with Tukey's multiple comparisons. ***, p<0.001.</p>
- C. Normalized cell viability of GSC 3028 following transduction with sgRNAs targeting SNX10 compared to a non-targeting sgRNA (sgCONT) over a 6-day time course. N = 3. Data are presented as mean ± SD. Significance was determined by two-way ANOVA with Tukey's multiple comparisons. ***, p<0.001.</p>
- D. Kaplan-Meier curve showing survival of all glioblastoma patients in the CGGA datasets stratified by the median mRNA expression of SNX10. Logrank analysis was used for statistical analysis.
- E. Kaplan-Meier curve showing survival of glioblastoma patients of proneural subtype in TCGA datasets stratified by the median mRNA expression of SNX10. Log-rank analysis was used for statistical analysis.
- F. Kaplan-Meier curve showing survival of glioblastoma patients of mesenchymal subtype in TCGA datasets stratified by the median mRNA expression of SNX10. Log-rank analysis was used for statistical analysis.
- G. Kaplan-Meier curve showing survival of glioblastoma patients of classical subtype in TCGA datasets stratified by the median mRNA expression of SNX10. Log-rank analysis was used for statistical analysis.



Figure S7: Model figure of target identification approach and mechanism of action

(Left) Model figure of target identification approach through combinatorial epigenetic and transcriptional profiling followed by a CRISPR-Cas9 loss-of-function dropout screen identifies SNX10. (**Right**) Model figure of mechanism of action of SNX10. SNX10 functions to maintain PDGF receptor signaling through control of endosomes to maintain glioblastoma stem cell proliferation and self-renewal properties.



Full unedited gel for Figure 3E



SNX10 Monoclonal Antibody (OTI3F1) Origene Cat # TA808884

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074

Full unedited gel for Figure 7C



Goat polyclonal antibody to SOX2 R&D Systems Cat # AF2018

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074



Full unedited gel for Figure 8E



SNX10 Monoclonal Antibody (OTI3F1) Origene Cat # TA808884

PDGF Receptor β (28E1) Rabbit mAb CST #3169

Rabbit monoclonal antibody to EGF Receptor (D38B1) CST Cat # 4267

FGF Receptor 1 (D8E4) XP® Rabbit mAb #9740 CST Cat #9740

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074

HER2/ErbB2 (D8F12) XP® Rabbit mAb #4290









PDGF Receptor β (28E1) Rabbit mAb CST #3169

Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb CST#9145

STAT3(79D7) Rabbit mAb #4904

Rabbit monoclonal antibody to Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) CST Cat #4370

Rabbit monoclonal antibody to p44/42 MAPK (Erk1/2) (137F5) CST Cat #4695

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074

CW468

Full unedited gel for Figure 8G



PDGF Receptor β (28E1) Rabbit mAb CST #3169

STAT3(79D7) Rabbit mAb #4904

Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb CST#9145

Monoclonal ANTI-FLAG® M2 antibody produced in mouse (Clone M2) Sigma F1804

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074





Full unedited gel for Figure 11C





PDGF Receptor β (28E1) Rabbit mAb CST #3169

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074

Ubiquitin (E4I2J) Rabbit mAb CST #43124



Monoclonal ANTI-FLAG® M2 antibody produced in mouse (Clone M2) Sigma F1804 Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074 SNX10 Monoclonal Antibody (OTI3F1) Origene Cat # TA808884

Full unedited gel for Figure S4B-D







CW468

PDGF Receptor β (28E1) Rabbit mAb CST #3169

Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb CST#9145

STAT3(79D7) Rabbit mAb #4904

Rabbit monoclonal antibody to Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) CST Cat #4370

Rabbit monoclonal antibody to p44/42 MAPK (Erk1/2) (137F5) CST Cat #4695

Rabbit polyclonal antibody to Phospho-Akt (Ser473) (D9E) CST Cat # 9271

Rabbit monoclonal antibody to AKT (clone C67E7) CST Cat # 4691

Mouse monoclonal antibody to alpha-Tubulin (clone B-5-1-2) Sigma Aldrich, Cat T6074

Ubiquitin (E4I2J) Rabbit mAb CST #43124

Monoclonal ANTI-FLAG® M2 antibody produced in mouse (Clone M2) Sigma F1804